Regeneron missed Wall Street estimates for first-quarter results on Tuesday, hurt by waning demand for its blockbuster eye ...

Evan David Seigerman, BMO head of healthcare research, joins 'Squawk Box' to break down Pfizer and Regeneron's quarter ...

New data presented at AACR supports adding pembrolizumab before and after surgery in patients with newly diagnosed locally ...

Shares of biotech company Regeneron (NASDAQ:REGN) fell 9.6% in the morning session after the company reported weak ...

After consecutive setbacks at the FDA, Regeneron's string of recent troubles with its Eylea franchise is continuing to pull ...

Regeneron Pharmaceuticals stock was among the biggest S&P 500 and Nasdaq decliners Tuesday after the biotech firm reported ...

Regeneron boosts antibody profits with higher Dupixent sales and expands biologics production via FUJIFILM Diosynth ...

The Tarrytown, New York-based company said it had profit of $7.27 per share. Earnings, adjusted for one-time gains and costs, came to $8.22 per share. The results fell short of Wall Street ...

Major U.S. stock indexes were higher at midday as markets awaited more information about potential White House tariff deals.

Regeneron (REGN) delivered earnings and revenue surprises of -2.49% and 7.53%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Explore Regeneron's Q1 2025 earnings with updates on Dupixent growth, EYLEA challenges, FDA hurdles, and upcoming approvals.